$PRME
Prime Medicine, Inc. Stock $prme

$prme Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000162828023027772 Filed on August 07, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.49M	$10.66M	$7.365M
YoY Change	58.75%	44.74%	217.32%
% of Gross Profit
Research & Development	$40.97M	$34.60M	$18.94M
YoY Change	63.57%	82.68%	232.57%
% of Gross Profit
Depreciation & Amortization	$1.236M	$1.118M	$430.0K
YoY Change	95.88%	160.0%	150.0%
% of Gross Profit
Operating Expenses	$51.46M	$45.26M	$26.31M
YoY Change	62.56%	72.05%	228.16%
Operating Profit	-$51.46M	-$45.26M	-$26.31M
YoY Change	62.56%	72.05%
Interest Expense	-$1.580M	$260.0K	-$3.723M
YoY Change	-188.32%	-106.98%	-138.19%
% of Operating Profit
Other Income/Expense, Net	$643.0K	$2.903M	$238.0K
YoY Change	-11.68%	1119.75%	23700.0%
Pretax Income	-$50.82M	-$42.35M	-$29.79M
YoY Change	74.41%	42.16%	-1817.99%
Income Tax	-$108.0K	$31.00K	-$442.0K
% Of Pretax Income
Net Earnings	-$50.71M	-$42.39M	-$35.64M
YoY Change	41.99%	18.92%	745.17%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.55	-$0.47	-$1.76
Diluted Earnings Per Share	-$0.55	-$0.47	-$0.38
COMMON SHARES
Basic Shares Outstanding	97.30M shares	97.23M shares	20.23M shares
Diluted Shares Outstanding	91.85M shares	90.47M shares	20.23M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$165.3M	$207.6M	$180.6M
YoY Change	12.71%	14.96%
Cash & Equivalents	$43.96M	$120.6M	$92.24M
Short-Term Investments	$121.4M	$87.04M	$88.36M
Other Short-Term Assets	$19.20M	$10.87M	$1.002M
YoY Change	780.73%	985.03%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$184.5M	$218.5M	$181.6M
YoY Change	23.98%	20.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$22.03M	$20.56M	$47.63M
YoY Change	-53.43%	-56.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.816M	$1.816M	$18.37M
YoY Change	-90.5%	-90.11%
Total Long-Term Assets	$54.61M	$62.38M	$65.99M
YoY Change	-17.77%	-5.48%
TOTAL ASSETS
Total Short-Term Assets	$184.5M	$218.5M	$181.6M
Total Long-Term Assets	$54.61M	$62.38M	$65.99M
Total Assets	$239.1M	$280.9M	$247.6M
YoY Change	11.09%	13.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.12M	$5.490M	$5.885M
YoY Change	243.57%	-6.71%
Accrued Expenses	$14.02M	$21.73M	$16.75M
YoY Change	-16.32%	29.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$39.37M	$28.72M	$23.83M
YoY Change	77.18%	20.51%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.800M	$11.93M	$22.76M
YoY Change	-70.8%	-47.57%
Total Long-Term Liabilities	$5.800M	$11.93M	$22.76M
YoY Change	-70.8%	-47.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$39.37M	$28.72M	$23.83M
Total Long-Term Liabilities	$5.800M	$11.93M	$22.76M
Total Liabilities	$45.19M	$40.76M	$46.86M
YoY Change	6.17%	-13.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$425.7M	-$375.0M
YoY Change	67.66%
Common Stock	$2.000K	$2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$194.0M	$240.1M	$200.7M
YoY Change
Total Liabilities & Shareholders Equity	$239.1M	$280.9M	$247.6M
YoY Change	11.09%	13.44%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$50.71M	-$42.39M	-$35.64M
YoY Change	41.99%	18.92%	745.17%
Depreciation, Depletion And Amortization	$1.236M	$1.118M	$430.0K
YoY Change	95.88%	160.0%	150.0%
Cash From Operating Activities	-$39.17M	-$40.82M	-$20.22M
YoY Change	30.14%	101.85%	79.14%
INVESTING ACTIVITIES
Capital Expenditures	$2.900M	$1.976M	$4.802M
YoY Change	-39.47%	-58.85%	147.02%
Acquisitions
YoY Change
Other Investing Activities	-$34.86M	$29.84M	-$45.99M
YoY Change	299.77%	-164.88%	-39.65%
Cash From Investing Activities	-$37.77M	$27.86M	-$50.79M
YoY Change	179.55%	-154.85%	-35.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	320.0K	75.00K	-624.0K
YoY Change	-146.85%	-112.02%	-100.23%
NET CHANGE
Cash From Operating Activities	-39.17M	-40.82M	-20.22M
Cash From Investing Activities	-37.77M	27.86M	-50.79M
Cash From Financing Activities	320.0K	75.00K	-624.0K
Net Change In Cash	-76.62M	-12.89M	-71.64M
YoY Change	72.99%	-82.01%	-139.59%
FREE CASH FLOW
Cash From Operating Activities	-$39.17M	-$40.82M	-$20.22M
Capital Expenditures	$2.900M	$1.976M	$4.802M
Free Cash Flow	-$42.07M	-$42.80M	-$25.03M
YoY Change	20.58%	71.02%	89.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.32167
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-156241000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-81782000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-81782000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.31
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90467298	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90467298	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20227343	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20227343	shares
CY2022Q1	prme	Additional Paid In Capital Reclassification Of Forward Contract Value AdditionalPaidInCapitalReclassificationOfForwardContractValue	12020000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1123000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-166943000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1346000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-29348000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-195063000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-81782000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-53188000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	6304000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4222000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5264000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2468000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2170000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	723000	usd
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-1438000	usd
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-8208000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1403000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-249000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-171000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-974000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5299000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	43000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1104000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2428000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3438000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-30851000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6569000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4258000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-82382000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-71016000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	65000000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	62000000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	45659000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	74744000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3975000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6490000	usd
	prme	Payments For Security Deposits PaymentsForSecurityDeposits	170000	usd
	prme	Payments For Security Deposits PaymentsForSecurityDeposits	664000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15196000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19898000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1896000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	143000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	143000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1896000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-67043000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-92810000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201116000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198545000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	134073000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	105735000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	134073000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	105735000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	13496000	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	13496000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	120577000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92239000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3265000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	28573000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	712000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2583000	usd
	prme	Settlement Of Forward Contract SettlementOfForwardContract	0	usd
	prme	Settlement Of Forward Contract SettlementOfForwardContract	12020000	usd
	prme	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	0	usd
	prme	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	244000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-375000000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	207600000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and </span></div>assumptions reflected within these condensed consolidated financial statements include, but are not limited to the valuation of the Company’s common stock and stock-based awards, and the valuation of the related party forward contract liability. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ materially from those estimates or assumptions.
CY2023Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	206703000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	226812000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	80920000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	275000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	80645000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	98851000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	384000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	98467000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	80645000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	98467000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25559000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21840000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5001000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2831000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20558000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19009000	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1118000	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	430000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2170000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	723000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3954265	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.43
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3504319	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.76
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	60702	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.87
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	193234	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.36
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7204648	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.48
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1528964	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.64
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7204648	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.48
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3583000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1345000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5264000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2468000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	6465000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	14960000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3915000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1683000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	567000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	27590000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2148000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	25442000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-42385000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-29348000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-81782000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-53188000	usd
CY2023Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	usd
CY2022Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6293000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	12517000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-42385000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42385000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35641000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-35641000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-81782000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-81782000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-65705000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-65705000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90467298	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90467298	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20227343	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20227343	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89769970	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	89769970	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19871750	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19871750	shares
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.76
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.76
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.31
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13466614	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	67513282	shares

Files In Submission

Name	View Source	Status
0001628280-23-027772-index-headers.html	Edgar Link	pending
0001628280-23-027772-index.html	Edgar Link	pending
0001628280-23-027772.txt	Edgar Link	pending
0001628280-23-027772-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prme-20230630.htm	Edgar Link	pending
prme-20230630.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
prme-20230630_def.xml	Edgar Link	unprocessable
q22023ex10-1.htm	Edgar Link	pending
q22023ex10-1001.jpg	Edgar Link	pending
q22023ex10-1002.jpg	Edgar Link	pending
q22023ex10-1003.jpg	Edgar Link	pending
q22023ex10-1004.jpg	Edgar Link	pending
q22023ex10-1005.jpg	Edgar Link	pending
q22023ex10-1006.jpg	Edgar Link	pending
q22023ex10-1007.jpg	Edgar Link	pending
q22023ex10-1008.jpg	Edgar Link	pending
q22023ex10-1009.jpg	Edgar Link	pending
q22023ex10-1010.jpg	Edgar Link	pending
q22023ex10-1011.jpg	Edgar Link	pending
q22023ex10-1012.jpg	Edgar Link	pending
q22023ex10-1013.jpg	Edgar Link	pending
q22023ex10-1014.jpg	Edgar Link	pending
q22023ex10-1015.jpg	Edgar Link	pending
q22023ex10-1016.jpg	Edgar Link	pending
q22023ex10-1017.jpg	Edgar Link	pending
q22023ex10-1018.jpg	Edgar Link	pending
q22023ex10-1019.jpg	Edgar Link	pending
q22023ex10-1020.jpg	Edgar Link	pending
q22023ex10-1021.jpg	Edgar Link	pending
q22023ex10-1022.jpg	Edgar Link	pending
q22023ex10-1023.jpg	Edgar Link	pending
q22023ex10-1024.jpg	Edgar Link	pending
q22023ex10-1025.jpg	Edgar Link	pending
q22023ex10-1026.jpg	Edgar Link	pending
q22023ex10-1027.jpg	Edgar Link	pending
q22023ex10-1028.jpg	Edgar Link	pending
q22023ex10-1029.jpg	Edgar Link	pending
q22023ex10-1030.jpg	Edgar Link	pending
q22023ex10-1031.jpg	Edgar Link	pending
q22023ex10-1032.jpg	Edgar Link	pending
q22023ex102.htm	Edgar Link	pending
q22023ex103.htm	Edgar Link	pending
q22023ex104.htm	Edgar Link	pending
q22023ex105.htm	Edgar Link	pending
q22023ex311.htm	Edgar Link	pending
q22023ex312.htm	Edgar Link	pending
q22023ex321.htm	Edgar Link	pending
q22023ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
prme-20230630_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
prme-20230630_cal.xml	Edgar Link	unprocessable
prme-20230630_pre.xml	Edgar Link	unprocessable
prme-20230630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRME
Prime Medicine, Inc. Stock $prme

2023 Q3 Form 10-Q Financial Statement

#000162828023027772 Filed on August 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRME Prime Medicine, Inc. Stock $prme

2023 Q3 Form 10-Q Financial Statement

#000162828023027772 Filed on August 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRME
Prime Medicine, Inc. Stock $prme